Advertisement
PROK vs TSHA
Which Stock Would AI Choose? ProKidney Corp. (PROK) vs. Taysha Gene Therapies (TSHA) Stock Comparison
Key Takeaways
- PROK (ProKidney Corp.) and TSHA (Taysha Gene Therapies) are both pre-commercial, clinical-stage biotechnology companies, but they target different diseases and sit at different stages of the regulatory timeline.
- TSHA is closer to a potential regulatory filing, having completed dosing in its pivotal REVEAL and ASPIRE trials, while PROK expects pivotal Phase 3 topline data in the second quarter of 2027.
- TSHA holds a larger cash balance (about $277 million as of Q1 2026) with a runway into 2028, versus roughly $182 million for PROK, supporting operations into mid-2027.
- Both names carry elevated clinical and regulatory risk, making relative performance highly sensitive to data readouts and FDA (U.S. Food and Drug Administration) feedback.
- TSHA generated meaningful collaboration revenue in 2025, whereas PROK remains essentially pre-revenue.
- For more information on each company's major developments and daily price action, explore the PROK Major News and PROK Today's Price Move pages, as well as TSHA Major News and TSHA Today's Price Move.
- To see how algorithmic systems are positioning across the market, visit the curated Trending AI Robots section.
Introduction
This stock comparison examines two clinical-stage biotechnology companies, PROK and TSHA, whose valuations hinge almost entirely on the outcome of late-stage clinical programs and regulatory decisions. ProKidney is developing a cell therapy for chronic kidney disease, while Taysha is advancing a gene therapy for Rett syndrome, a rare neurodevelopmental disorder. For growth-oriented and biotechnology-specialist investors who weigh clinical catalysts, cash runway, and regulatory positioning, these two names offer a useful contrast in market positioning: one is moving toward a potential near-term filing, while the other is years from a pivotal readout.
PROK Overview and Recent Performance
ProKidney Corp. (PROK) is a late clinical-stage cell therapy company focused on chronic kidney disease (CKD). Its lead candidate, rilparencel (REACT), is an autologous cell therapy derived from a patient's own renal cells, designed to preserve kidney function in patients with advanced CKD and type 2 diabetes.
In recent weeks, the company has emphasized execution on its Phase 3 PROACT 1 study, having completed enrollment of the cohort contributing to the accelerated approval efficacy analysis. Peer-reviewed Phase 2 data published earlier in the year and FDA alignment on using eGFR slope (estimated glomerular filtration rate, a measure of kidney function) as a surrogate endpoint have supported sentiment. The pivotal topline readout is not expected until the second quarter of 2027, a timeline that leaves the stock exposed to extended clinical and financing risk. The company ended its most recent quarter with roughly $182 million in cash and marketable securities, funding operations into mid-2027.
TSHA Overview and Recent Performance
Taysha Gene Therapies (TSHA) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS). Its lead program, TSHA-102, targets Rett syndrome, a rare disorder caused by mutations in the MECP2 gene.
Recent market activity has been shaped by steady clinical and regulatory progress. The company completed dosing in its pivotal REVEAL trial and its ASPIRE trial in the second quarter of 2026, and it has maintained written alignment with the FDA on chemistry, manufacturing, and controls (CMC) requirements supporting a potential Biologics License Application (BLA). TSHA-102 holds Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations. Financially, Taysha reported about $277 million in cash and cash equivalents as of the first quarter of 2026, with runway into 2028, and it generated collaboration revenue of roughly $9.8 million in 2025.
Trending AI Robots
Tickeron operates a large ecosystem of AI trading bots that monitor thousands of tickers across diverse strategies, timeframes, and risk profiles. Because not every bot suits every market regime, Tickeron curates a dedicated Trending AI Robots page featuring only the systems best matched to current conditions. These bots differ in trading style, strategy, performance statistics, and the specific sets of tickers they follow, giving traders a way to compare automated approaches rather than relying on a single model. For investors tracking names such as PROK and TSHA, reviewing these curated bots can add a data-driven layer to fundamental analysis. Explore the Trending AI Robots page to see which algorithms are currently aligned with the market.
Head-to-Head Comparison
The two companies diverge most sharply on development stage and capital position. TSHA is nearer to a potential registration event, with pivotal dosing complete and a BLA-enabling manufacturing campaign underway, whereas PROK is still building toward a data readout nearly a year away. In terms of liquidity, Taysha's larger cash balance and extended runway into 2028 offer greater near-term financial stability than ProKidney's runway into mid-2027.
On the growth-driver front, Taysha benefits from a rare-disease franchise with limited competition and multiple regulatory designations, while ProKidney is pursuing a broad chronic disease population with substantial commercial potential but a longer path to market. Risk profiles also differ: both face binary clinical outcomes, but Taysha's nearer-term catalysts are concentrated in the coming months, while ProKidney's value remains tied to 2027 data. Sector exposure is similar — both sit in biotechnology — yet their respective catalysts and financing needs create distinct risk-reward trade-offs.
Tickeron AI Verdict
Based on observable factors such as proximity to a regulatory catalyst, cash runway, and the consistency of recent clinical and regulatory progress, Tickeron's AI would likely assign a more favorable near-term positioning to TSHA. The completion of pivotal dosing, alignment with the FDA on manufacturing, and a longer cash runway provide a relatively more defined catalyst path. By contrast, PROK offers a larger addressable-market thesis but carries a longer wait for pivotal data. These are probabilistic assessments of momentum and positioning rather than guarantees, and relative rankings can shift rapidly with new clinical data or financing developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PROK is a Hold and TSHA is a Hold.
PROK in downward trend: price dove below 50-day moving average on October 12, 2026
PROK moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 50 of 55 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PROK as a result. In 74 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for PROK turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 45 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PROK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for PROK entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PROK's RSI Indicator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 69 cases where PROK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where PROK advanced for three days, in 202 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PROK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.270) is normal, around the industry mean (3.498). P/E Ratio (-2.073) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (344.828) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. PROK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PROK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TSHA's RSI Indicator ascending out of oversold territory
The RSI Indicator for TSHA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 33 of the 37 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on TSHA as a result. In 71 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for TSHA just turned positive on October 21, 2026. Looking at past instances where TSHA's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
Following a +6.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSHA advanced for three days, in 213 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TSHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 53 cases where TSHA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
The 50-day moving average for TSHA moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TSHA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.643) is normal, around the industry mean (3.498). P/E Ratio (-10.561) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. TSHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TSHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TSHA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | |
P/E GROWTH RATING 1..100 | 20 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| PROK | TSHA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 2 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 88% |
| Advances ODDS (%) | 3 days ago 79% | 3 days ago 82% |
| Declines ODDS (%) | 9 days ago 86% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 72% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PROK’s FA Score shows that 1 FA rating(s) are green while TSHA’s FA Score has 2 green FA rating(s).
- PROK’s FA Score: 1 green, 4 red.
- TSHA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PROK’s TA Score shows that 4 TA indicator(s) are bullish while TSHA’s TA Score has 5 bullish TA indicator(s).
- PROK’s TA Score: 4 bullish, 5 bearish.
- TSHA’s TA Score: 5 bullish, 4 bearish.
Price Growth
PROK (@Biotechnology) experienced а +3.74% price change this week, while TSHA (@Biotechnology) price change was +4.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
PROK is expected to report earnings on Mar 25, 2027.
TSHA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PROK and
Correlation & Price change
A.I.dvisor indicates that over the last year, PROK has been loosely correlated with RXRX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PROK jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To PROK | 1D Price Change % | ||
|---|---|---|---|---|
| PROK | 100% | -3.48% | ||
| RXRX - PROK | 50% Loosely correlated | -6.70% | ||
| SANA - PROK | 49% Loosely correlated | -1.42% | ||
| EDIT - PROK | 46% Loosely correlated | -8.91% | ||
| NKTX - PROK | 45% Loosely correlated | -15.09% | ||
| TSHA - PROK | 44% Loosely correlated | -2.17% | ||
More | ||||
TSHA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TSHA has been loosely correlated with SLDB. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if TSHA jumps, then SLDB could also see price increases.
| Ticker / NAME | Correlation To TSHA | 1D Price Change % | ||
|---|---|---|---|---|
| TSHA | 100% | -2.17% | ||
| SLDB - TSHA | 54% Loosely correlated | +2.14% | ||
| STOK - TSHA | 51% Loosely correlated | -1.80% | ||
| MGTX - TSHA | 51% Loosely correlated | +1.37% | ||
| FDMT - TSHA | 51% Loosely correlated | -0.16% | ||
| KYTX - TSHA | 50% Loosely correlated | -1.74% | ||
More | ||||